C.J.A. Punt

924 total citations
26 papers, 624 citations indexed

About

C.J.A. Punt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, C.J.A. Punt has authored 26 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in C.J.A. Punt's work include Colorectal Cancer Treatments and Studies (13 papers), Genetic factors in colorectal cancer (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). C.J.A. Punt is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Genetic factors in colorectal cancer (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). C.J.A. Punt collaborates with scholars based in Netherlands, France and United Kingdom. C.J.A. Punt's co-authors include Jonathan A. Ledermann, Bernard Nordlinger, Frits van Coevorden, Murielle Mauer, Erik H.J.G. Aarntzen, Halfdan Sørbye, Gosse J. Adema, P. M. Schlag, I. Jolanda M. de Vries and Thomas Gruenberger and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Annals of Oncology.

In The Last Decade

C.J.A. Punt

25 papers receiving 612 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.J.A. Punt Netherlands 11 299 216 171 161 99 26 624
Jobst C. von Einem Germany 15 456 1.5× 178 0.8× 116 0.7× 114 0.7× 140 1.4× 33 659
Shozo Mori Japan 11 288 1.0× 201 0.9× 139 0.8× 84 0.5× 140 1.4× 63 688
Binglin Yue United States 16 320 1.1× 335 1.6× 66 0.4× 75 0.5× 212 2.1× 41 857
Christian Teschendorf Germany 12 222 0.7× 125 0.6× 66 0.4× 42 0.3× 75 0.8× 28 621
Siobhan Ng Australia 12 355 1.2× 360 1.7× 42 0.2× 60 0.4× 87 0.9× 33 708
W. Mai United States 9 155 0.5× 397 1.8× 60 0.4× 103 0.6× 57 0.6× 35 708
Mao-Bin Meng China 13 261 0.9× 255 1.2× 61 0.4× 54 0.3× 82 0.8× 17 628
Yong-Wen Song China 14 302 1.0× 127 0.6× 71 0.4× 45 0.3× 144 1.5× 51 600
Irini Karapanagiotou‐Schenkel Germany 10 98 0.3× 167 0.8× 57 0.3× 100 0.6× 61 0.6× 16 435
Maria Scardoni Italy 15 422 1.4× 136 0.6× 42 0.2× 84 0.5× 84 0.8× 21 824

Countries citing papers authored by C.J.A. Punt

Since Specialization
Citations

This map shows the geographic impact of C.J.A. Punt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J.A. Punt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J.A. Punt more than expected).

Fields of papers citing papers by C.J.A. Punt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J.A. Punt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J.A. Punt. The network helps show where C.J.A. Punt may publish in the future.

Co-authorship network of co-authors of C.J.A. Punt

This figure shows the co-authorship network connecting the top 25 collaborators of C.J.A. Punt. A scholar is included among the top collaborators of C.J.A. Punt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.J.A. Punt. C.J.A. Punt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2024). Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Annals of Oncology. 36(3). 277–284. 27 indexed citations
2.
3.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. European Journal of Cancer. 72. S5–S5. 1 indexed citations
4.
5.
6.
Cuba, Erienne M.V. de, Pétur Snæbjörnsson, Daniëlle A.M. Heideman, et al.. (2015). Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. International Journal of Cancer. 138(5). 1139–1145. 43 indexed citations
7.
Tanis, E., Bernard Nordlinger, Murielle Mauer, et al.. (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 50(5). 912–919. 161 indexed citations
8.
Kessel, Charlotte S. van, Mariam Samim, Miriam Koopman, et al.. (2013). Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. European Journal of Cancer. 49(11). 2486–2493. 32 indexed citations
9.
Aarntzen, Erik H.J.G., Carl G. Figdor, Gosse J. Adema, C.J.A. Punt, & I. Jolanda M. de Vries. (2009). Dendritic cell vaccination and immune monitoring. ISBT Science Series. 4(1). 18–23. 2 indexed citations
10.
Bleeker‐Rovers, Chantal P., et al.. (2009). Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab: a case report.. PubMed. 67(2). 69–71. 7 indexed citations
11.
Mulder, Sasja F., et al.. (2009). 1104 Immunological response to influenza vaccine in cancer patients undergoing treatment with sunitinib or sorafenib. European Journal of Cancer Supplements. 7(2). 116–116. 2 indexed citations
12.
Aarntzen, Erik H.J.G., Carl G. Figdor, Gosse J. Adema, C.J.A. Punt, & I. Jolanda M. de Vries. (2008). Dendritic cell vaccination and immune monitoring. Cancer Immunology Immunotherapy. 57(10). 1559–1568. 76 indexed citations
13.
Herpen, C. van, Joachim Drevs, Hester van Cruijsen, et al.. (2007). Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. Journal of Clinical Oncology. 25(18_suppl). 3560–3560. 10 indexed citations
14.
Cruijsen, Hester van, Emile E. Voest, Carla M. van Herpen, et al.. (2006). Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. Journal of Clinical Oncology. 24(18_suppl). 3017–3017. 13 indexed citations
15.
Tol, J. & C.J.A. Punt. (2006). Treatment of liver metastases from colorectal cancer.. PubMed. 64(5). 133–5. 9 indexed citations
16.
Eggermont, A.M.M., Stefan Suciu, W. Ruka, et al.. (2003). 1067 Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III. European Journal of Cancer Supplements. 1(5). S319–S319. 3 indexed citations
17.
Punt, C.J.A., Mary Linton B. Peters, C.J. Bol, et al.. (1999). Phase I trial with farnesyltransferase inhibitor R115777 in patients (pts) with advanced solid tumors. European Journal of Cancer. 35. S291–S291. 1 indexed citations
18.
Kamm, Y.J.L., et al.. (1998). 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. Anti-Cancer Drugs. 9(5). 371–380. 14 indexed citations
19.
Eskens, Ferry A.L.M., C.J.A. Punt, & C.A.H.H.V.M. Verhagen. (1996). Trombo-embolische complicaties van centraal-veneuze katheters. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 140(46). 2302–2302. 2 indexed citations
20.
Vermorken, J. B., et al.. (1995). 962 Bone marrow protection by amifostine (AMI) in patients treated with carboplatin (CARBO): A phase I study. European Journal of Cancer. 31. S200–S200. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jobst C. von Einem Breakdown of academic impact, for papers by Shozo Mori Breakdown of academic impact, for papers by Binglin Yue Breakdown of academic impact, for papers by Christian Teschendorf Breakdown of academic impact, for papers by Siobhan Ng Breakdown of academic impact, for papers by W. Mai Breakdown of academic impact, for papers by Mao-Bin Meng Breakdown of academic impact, for papers by Yong-Wen Song Breakdown of academic impact, for papers by Irini Karapanagiotou‐Schenkel Breakdown of academic impact, for papers by Maria Scardoni
Rankless by CCL
2026